Genmab gets fresh Buy call from HC Wainwright, shares stay in focus on Nasdaq and Copenhagen

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:40.

Genmab A/S (DK0010272202) remains on the radar of Wall Street and Nordic investors after HC Wainwright & Co. reiterated its Buy rating and 38 dollar price target for the Nasdaq-listed shares on June 23, 2026, according to a GuruFocus summary of the analyst note.GuruFocus report on the HC Wainwright update

What the HC Wainwright note signals

The HC Wainwright report maintains Genmab at Buy with a 38 dollar target, unchanged from the prior rating, and is attributed to analyst Raghuram Selvaraju, according to GuruFocus.GuruFocus report on the HC Wainwright update The note highlights Genmab’s growth prospects despite a prior reduction of the target from 40 to 38 dollars, indicating a still constructive view on the biotech’s pipeline and commercial assets.GuruFocus report on the HC Wainwright update

GuruFocus calculates a GF Value of 35.19 dollars for the Genmab shares versus a referenced market price of 25.61 dollars on Nasdaq GMAB, implying a 27.2 percent discount in that framework.GuruFocus valuation snapshot for Genmab The service assigns Genmab an overall GF Score of 95 out of 100, pointing to a strong composite profile on growth, profitability and momentum metrics in its methodology.GuruFocus valuation snapshot for Genmab

Consensus picture and dual listing

On the Copenhagen exchange, Genmab shares closed at 1,708.50 Danish kroner on June 23, a gain of 3.20 percent on the day with trading volume of 118,575 shares, according to MarketScreener data.MarketScreener price data for Genmab in Copenhagen The prior day’s close stood at 1,655.50 kroner, reflecting a two-day advance in the Danish line of the stock.MarketScreener price data for Genmab in Copenhagen

Finanzen100 quotes the German-traded Genmab line under symbol GE9 at around 222.60 to 224.50 euros per share in Xetra-related trading, offering euro-based exposure alongside the primary listings on Nasdaq Copenhagen and Nasdaq in New York.Finanzen100 quote overview for Genmab MarketScreener aggregates an average analyst target price of 2,313.13 kroner for Genmab, pointing to a higher long-term expectation from the broader sell-side community compared with the current Copenhagen price level.MarketScreener consensus and news on Genmab

The product behind the stock

Genmab’s commercial and late-stage portfolio is anchored by epcoritamab, a bispecific antibody targeting CD3 and CD20 that is being developed with AbbVie and has shown high response rates in elderly patients with newly diagnosed diffuse large B-cell lymphoma according to recent clinical data presented in mid-June 2026.Finanzen100 summary of recent Genmab epcoritamab data

Where the stock trades today

Genmab shares (DK0010272202) last traded on Nasdaq Copenhagen at 1,708.50 Danish kroner on 2026-06-23, while the German line around symbol GE9 was indicated near 223 euros in Xetra-related trading on the same date.

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. Data and estimates are based on sources considered reliable but cannot be guaranteed.